BMS taps biotech analyst from Goldman Sachs to lead long-term strategy
Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when deciding on a new tactical leader. The Big Pharma has hired physician-turned-analyst Chris Shibutani, M.D., as executive vice president and chief strategy officer, BMS announced on June 9.
Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when deciding on a new tactical leader. The Big Pharma has hired physician-turned-analyst Chris Shibutani, M.D., as executive vice president and chief strategy officer, BMS announced on June 9.
